Biodetoksa - Company finances
|
EUR
|
2019
From: 2019-08-27
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | 3,142 | 8,480 | 9,221 | 11,951 | 10,210 | 12,395 | 15,116 |
| Profit before tax | 710 | 2,837 | 443 | 3,150 | -827 | 1,197 | -2,779 |
| Net profit | 710 | 2,695 | 421 | 2,992 | -827 | 1,178 | -2,779 |
| Equity | 720 | 3,415 | 3,835 | 6,827 | 6,000 | 7,178 | 4,399 |
| Liabilities | - | - | - | 1,597 | 534 | 534 | 2,492 |
| Non-current assets | 0 | 0 | 1,245 | 956 | 666 | 376 | 708 |
| Current assets | 1,690 | 4,098 | 4,140 | 7,468 | 5,868 | 7,336 | 6,183 |
| Total assets | 1,690 | 4,098 | 5,385 | 8,424 | 6,534 | 7,712 | 6,891 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 158 | - | 19 |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | +169.9% | +8.7% | +29.6% | -14.6% | +21.4% | +22.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 42.0% | 65.8% | 7.8% | 35.5% | -12.7% | 15.3% | -40.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 98.6% | 78.9% | 11.0% | 43.8% | -13.8% | 16.4% | -63.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 22.6% | 31.8% | 4.6% | 25.0% | -8.1% | 9.5% | -18.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 22.6% | 33.5% | 4.8% | 26.4% | -8.1% | 9.7% | -18.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | 0.2 | 0.1 | 0.1 | 0.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Biodetoksa - Social security debts
The company had no debts to Sodra
Biodetoksa - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Biodetoksa, MB (code 305237141) is a small partnership engaged in other human health activities n.e.c. In 2025, the company generated revenue of EUR 15.1K, up 21.9% year on year and 48.0% over two years. Despite this sales growth, net profit turned to a loss of EUR 2.8K in 2025, compared with a profit of EUR 1.2K in 2024 and a loss of EUR 827 in 2023. The 2025 profit margin was -18.4%, indicating weaker profitability than in the prior year. Over the three-year period, revenue moved steadily upward from EUR 10.2K in 2023 to EUR 12.4K in 2024 and EUR 15.1K in 2025, while earnings were more volatile and ended in a loss. At the end of 2025, total assets stood at EUR 6.9K, equity at EUR 4.4K and liabilities at EUR 2.5K. The equity ratio was 63.8% and debt-to-equity 0.57, while asset turnover reached 2.19x. ROE and ROA were negative in 2025.